[go: up one dir, main page]

CL2008001667A1 - Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño. - Google Patents

Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño.

Info

Publication number
CL2008001667A1
CL2008001667A1 CL2008001667A CL2008001667A CL2008001667A1 CL 2008001667 A1 CL2008001667 A1 CL 2008001667A1 CL 2008001667 A CL2008001667 A CL 2008001667A CL 2008001667 A CL2008001667 A CL 2008001667A CL 2008001667 A1 CL2008001667 A1 CL 2008001667A1
Authority
CL
Chile
Prior art keywords
neurological
trauma
pain
depression
treatment
Prior art date
Application number
CL2008001667A
Other languages
English (en)
Inventor
Joshua Clayton
Methvin Isaac
James Folmer
Ian Egle
James Empfield
Fupeng Ma
Abdelmalik Slassi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40093925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2008001667A1 publication Critical patent/CL2008001667A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

COMPUESTOS DE FÓRMULA I:<br /> EN DONDE R1 Y Q SON COMO SE DESCRIBEN EN LA MEMORIA DESCRIPTIVA Y PLIEGO, SUS SALES FARMACÉUTICAMENTE<br /> ACEPTABLES, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO PARA EL TRATAMIENTO DE TRASTORNOS<br /> NEUROLÓGICOS Y PSIQUIÁTRICOS TALES COMO ISQUEMIA CEREBRAL, TRAUMA EN LA MÉDULA ESPINAL, DOLOR, DEPRESIÓN<br /> Y TRASTORNOS DEL SUEÑO.<br />  
CL2008001667A 2007-06-07 2008-06-06 Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño. CL2008001667A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94255307P 2007-06-07 2007-06-07

Publications (1)

Publication Number Publication Date
CL2008001667A1 true CL2008001667A1 (es) 2009-03-06

Family

ID=40093925

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001667A CL2008001667A1 (es) 2007-06-07 2008-06-06 Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño.

Country Status (33)

Country Link
US (2) US8377940B2 (es)
EP (2) EP2444399B1 (es)
JP (2) JP5416696B2 (es)
KR (2) KR20100017640A (es)
CN (2) CN101679403B (es)
AR (1) AR066882A1 (es)
AU (1) AU2008260717B2 (es)
BR (1) BRPI0812889A2 (es)
CA (1) CA2690856C (es)
CL (1) CL2008001667A1 (es)
CO (1) CO6251287A2 (es)
CY (2) CY1113422T1 (es)
DK (2) DK2444399T3 (es)
EC (1) ECSP109856A (es)
ES (2) ES2531443T3 (es)
HR (2) HRP20120909T4 (es)
IL (1) IL202158A (es)
ME (1) ME01488B (es)
MX (1) MX2009013078A (es)
MY (1) MY158066A (es)
NZ (1) NZ582445A (es)
PE (1) PE20090328A1 (es)
PL (2) PL2444399T3 (es)
PT (2) PT2444399E (es)
RS (2) RS53845B1 (es)
RU (2) RU2470931C2 (es)
SA (1) SA08290344B1 (es)
SI (2) SI2167502T1 (es)
TW (1) TWI417100B (es)
UA (1) UA99129C2 (es)
UY (1) UY31124A1 (es)
WO (1) WO2008150233A1 (es)
ZA (1) ZA200908285B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
WO2009033703A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
SI2307389T1 (sl) 2008-06-20 2013-04-30 Astrazeneca Ab Derivat diabenzotiazepina in njegova uporaba
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP2013516462A (ja) * 2010-01-07 2013-05-13 アストラゼネカ・アクチエボラーグ 代謝調節型グルタミン酸受容体ポジティブアロステリックモジュレーターの製造方法−８７４
AU2011245737A1 (en) * 2010-04-30 2012-12-20 Astrazeneca Ab Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20200126026A (ko) 2014-01-21 2020-11-05 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MY204637A (en) 2014-01-21 2024-09-06 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2017014170A1 (ja) * 2015-07-17 2017-01-26 武田薬品工業株式会社 複素環化合物
CN108026088B (zh) 2015-07-17 2021-02-12 武田药品工业株式会社 用作hdac抑制剂的噁二唑衍生物
US10406146B2 (en) 2015-08-25 2019-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
CA3147523A1 (en) * 2019-07-18 2021-01-21 Abaxys Therapeutics Solid formulation of a 1,2,4-oxadiazole derivative
GB2621323A (en) 2022-08-03 2024-02-14 Sirgartan Holdings Ltd Treatments for obsessive compulsive disorder

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008803A (en) * 1932-04-18 1935-07-23 Stephan Engineering Corp Fuel atomizing and igniting means
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (es) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
AU1618697A (en) * 1996-02-06 1997-08-28 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
AU7548298A (en) 1997-05-30 1998-12-30 Meiji Seika Kaisha Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
CA2311131A1 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO2001064670A1 (en) * 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
CA2417638A1 (en) 2000-07-31 2002-02-07 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
JP4220249B2 (ja) * 2001-04-19 2009-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 サイクリックアミジン誘導体
CN1551866A (zh) 2001-08-09 2004-12-01 СҰҩƷ��ҵ��ʽ���� 羧酸衍生物化合物及包含这些化合物为活性成分的药物
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
MXPA05005580A (es) * 2002-11-26 2005-11-23 Maruishi Pharma Derivados de isoindolina.
CN100457731C (zh) 2003-03-26 2009-02-04 麦克公司 代谢型谷氨酸受体的苯甲酰胺调节剂
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
WO2005040157A2 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
EP1713775A4 (en) 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20070185095A1 (en) * 2004-02-18 2007-08-09 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
CN101768129B (zh) 2004-03-05 2012-05-23 日产化学工业株式会社 异*唑啉取代苯甲酰胺化合物的制备中间体
JPWO2005085214A1 (ja) 2004-03-05 2008-01-17 萬有製薬株式会社 ジアリール置換複素５員環誘導体
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CA2584598A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
CA2598531A1 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
NZ564254A (en) * 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
CN101309905A (zh) * 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
ES2340321T3 (es) * 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

Also Published As

Publication number Publication date
PT2167502E (pt) 2012-11-26
WO2008150233A1 (en) 2008-12-11
JP2010529118A (ja) 2010-08-26
ECSP109856A (es) 2010-02-26
EP2444399B1 (en) 2014-11-26
ZA200908285B (en) 2010-08-25
JP5416696B2 (ja) 2014-02-12
BRPI0812889A2 (pt) 2017-05-23
IL202158A (en) 2015-11-30
JP5815644B2 (ja) 2015-11-17
HK1142318A1 (en) 2010-12-03
IL202158A0 (en) 2010-06-16
CY1116150T1 (el) 2017-02-08
HK1166978A1 (en) 2012-11-16
RU2012141706A (ru) 2014-03-27
MY158066A (en) 2016-08-30
EP2167502A1 (en) 2010-03-31
PE20090328A1 (es) 2009-04-24
ES2393425T7 (es) 2013-11-22
AU2008260717A1 (en) 2008-12-11
CN102977086A (zh) 2013-03-20
CA2690856C (en) 2015-12-15
CN101679403B (zh) 2013-01-02
TWI417100B (zh) 2013-12-01
RU2470931C2 (ru) 2012-12-27
CY1113422T1 (el) 2016-06-22
RU2009147708A (ru) 2011-07-20
EP2444399A1 (en) 2012-04-25
HRP20120909T1 (en) 2012-12-31
US20100267740A1 (en) 2010-10-21
PL2444399T3 (pl) 2015-04-30
DK2167502T3 (da) 2012-12-03
AR066882A1 (es) 2009-09-16
CN101679403A (zh) 2010-03-24
US8377940B2 (en) 2013-02-19
JP2014055164A (ja) 2014-03-27
NZ582445A (en) 2012-03-30
MX2009013078A (es) 2010-01-15
DK2444399T3 (en) 2015-03-02
HRP20150210T1 (en) 2015-06-05
PL2167502T3 (pl) 2013-01-31
RS52526B2 (sr) 2018-06-29
SA08290344B1 (ar) 2011-10-03
AU2008260717B2 (en) 2012-01-19
SI2167502T1 (sl) 2012-12-31
CO6251287A2 (es) 2011-02-21
UY31124A1 (es) 2009-01-30
RS53845B1 (sr) 2015-08-31
RS52526B (sr) 2013-04-30
EP2167502B1 (en) 2012-09-19
CA2690856A1 (en) 2008-12-11
US8377939B2 (en) 2013-02-19
US20080306077A1 (en) 2008-12-11
TW200911254A (en) 2009-03-16
EP2167502B3 (en) 2013-07-10
PT2444399E (pt) 2015-03-04
KR20100017640A (ko) 2010-02-16
PL2167502T6 (pl) 2013-12-31
ES2393425T3 (es) 2012-12-21
ES2531443T3 (es) 2015-03-16
HRP20120909T4 (hr) 2013-11-08
ME01488B (me) 2014-04-20
UA99129C2 (ru) 2012-07-25
KR20150116907A (ko) 2015-10-16
CN102977086B (zh) 2015-04-01
EP2167502A4 (en) 2011-04-06
SI2444399T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
CL2008001667A1 (es) Compuestos derivados de 5-(1,2,4-oxadiazol-5-il)-2,3-dihidro-isoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y su uso en el tratamiento de trastornos neurologicos y psiquiatricos tales como isquemia cerebral, trauma en la medula espinal, dolor, depresion y trastornos del sueño.
CL2008001666A1 (es) Compuestos derivados de 5-([1,2,4]oxadiazol-3-il)-2,3-dihidro-osoindol-1-ona, modulador del receptor metabotropico de glutamato mglur2; composicion farmaceutica; y sus uso en el tratmiento de trastornos neurologicos y psiquiatricos como isquemia cerebral, trauma en la medula espinal, paro cardiaco, demencia, entre otros
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
CL2008003591A1 (es) Compuestos derivados de isoxazolo-piridina sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de trastornos cognitivos y alzheimer, mediado por la union al sitio de fijacion del receptor gaba a alfa 5.
EA200971143A1 (ru) Бензамидные mglur5 позитивные аллостерические модуляторы и способы их получения и применения
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
CU23911B1 (es) Derivados de amida espiro - ciclícas como moduladores de beta-2-adrenoreceptores útiles para el tratamiento de la bronquitis y el asma
CO6551729A2 (es) Moduladores alostericos positivos de receptores de m1 de quinolina amida
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
UY31219A1 (es) N-[3-(2,6-diclorofenil)-5-alquilo-1,2-oxazol-4-il carbamatos sustituidos y 1-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]ureas sustituidas asi como isomeros, sales farmacéuticas y usos de dichos compuestos
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
CO6501188A2 (es) Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1
PA8845601A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)
CR10682A (es) Compuestos de tiazol pirazolopirimidina
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
MY168937A (en) Ethynyl derivatives as modulators of mglur5 receptor activity
EA201291327A1 (ru) Замещенные 6-метилникотинамиды как позитивные аллостерические модуляторы mglur5